Perrigo's Three-S Plan Shows Early Progress as Portfolio Streamlining and Market Share Gains Support Reaffirmed 2026 Outlook

What happened

Perrigo's Q2 2026 results highlight continued market share growth in U.S. store-brand OTC and key European brands, indicating early traction from its Three-S plan. The company completed the divestiture of its Dermacosmetics business and is evaluating strategic options for Infant Formula and Oral Care, advancing portfolio streamlining. Management reaffirmed its full-year 2026 guidance and projected a sequentially stronger second half, signaling confidence in underlying operating trends. However, the release does not address the firm's elevated leverage (net debt/EBITDA ~7x) or the unresolved €1.64bn Irish tax dispute, which remain the primary risks to the equity story. While execution is improving, the thesis still depends on translating operational stability into sustainable deleveraging and legal resolution.

Implication

If Perrigo sustains market share gains, delivers the targeted cost savings, and resolves legacy balance-sheet and legal risks, the substantial gap between the current price and intrinsic value could narrow, rewarding patient investors; however, failure on any of these fronts would likely impair equity further given the fragile financial position.

Thesis delta

Execution of the Three-S plan and portfolio actions are progressing as expected, providing incremental confidence in management's turnaround. However, the core overhangs of high leverage and the Irish tax dispute remain unchanged, leaving the risk/reward profile heavily dependent on successful deleveraging and legal resolution. The news supports the existing POTENTIAL BUY stance but does not materially reduce the key risks.